EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1	osimertinib Sensitive: A1 - Approval osimertinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1	gefitinib Sensitive: A1 - Approval gefitinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1
EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1	amivantamab-vmjw Sensitive: A1 - Approval amivantamab-vmjw Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2
EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	EGFR L858R	Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2

EGFR L858R

Associations